Effects of Telmisartan Added to Angiotensin Converting Enzyme Inhibitors on Mortality and Morbidity in Hemodialysis Patients With Chronic Heart Failure - Telmisartan in Hemodialysis Patients With Chronic Heart Failure

Description:

Chronic heart failure (CHF) is highly prevalent in patients with end-stage renal disease (ESRD). Data in this patient population are sparse, and are usually extrapolated from data in nonuremic patients. The current trial sought to study the safety and efficacy of telmisartan added to angiotensin-converting enzyme inhibitors (ACEIs) and beta-blockers in patients with systolic CHF who were on hemodialysis.